Company facts
- Industry
- Pharmaceutical Preparations
- Headquarters
- Wilmette, Illinois
- Most recent report
- 8-K, filed Aug 12, 2026
- Incorporated
- Delaware
- Filings on record
- 517 filings
- On EDGAR
- CIK 1645469
- Fiscal year ends
- December
- Filer status
- Non-accelerated filer Smaller reporting company
Financials 8 of 40
News 8 of 118
- 8-K Quarterly results Aug 12, 2026
- 8-K Current report on a material event Jul 22, 2026
- 8-K Current report on a material event Jun 30, 2026
- 8-K Current report on a material event Jun 26, 2026
- 8-K Shareholder vote results Jun 23, 2026
- 8-K Current report on a material event May 29, 2026
- 8-K Current report on a material event May 19, 2026
- 8-K Quarterly results May 14, 2026
Prospectuses and Registrations 8 of 32
- S-8 POS Post-effective amendment to an employee plan registration Jul 22, 2026
- S-8 POS Post-effective amendment to an employee plan registration Jul 22, 2026
- S-8 POS Post-effective amendment to an employee plan registration Jul 22, 2026
- S-8 POS Post-effective amendment to an employee plan registration Jul 22, 2026
- S-8 Registration statement for an employee plan Jul 22, 2026
- 424B5 Prospectus supplement for an offering Sep 24, 2025
- S-3 Shelf registration statement Aug 29, 2025
- S-8 Registration statement for an employee plan Mar 31, 2025
Proxies 8 of 14
- DEFA14A Extra proxy material Apr 30, 2026
- DEF 14A Proxy statement for a shareholder vote Apr 30, 2026
- DEFA14A Extra proxy material May 23, 2025
- DEF 14A Proxy statement for a shareholder vote Apr 30, 2025
- DEF 14A Proxy statement for a shareholder vote Jul 22, 2024
- PRE 14A Preliminary proxy statement Jul 11, 2024
- DEFA14A Extra proxy material Apr 28, 2023
- DEF 14A Proxy statement for a shareholder vote Apr 28, 2023
Ownership 8 of 266
- SCHEDULE 13G/A Large holder reported a passive stake, amended Aug 12, 2026
- SCHEDULE 13G/A Large holder reported a passive stake, amended Aug 12, 2026
- 144/A Notice of a proposed sale of restricted stock, amended Jul 10, 2026
- 144 Notice of a proposed sale of restricted stock Jul 7, 2026
- 4 Insider reported a trade Jul 2, 2026
- 4 Insider reported a trade Jul 2, 2026
- 4 Insider reported a trade Jul 2, 2026
- 4 Insider reported a trade Jun 30, 2026
Other 8 of 47
- ARS Annual report sent to shareholders Apr 30, 2026
- EFFECT Notice that a registration became effective Sep 9, 2025
- CORRESP Reply to SEC staff Sep 5, 2025
- UPLOAD Comment letter from SEC staff Sep 4, 2025
- UPLOAD Comment letter from SEC staff Jul 25, 2025
- CORRESP Reply to SEC staff Jul 22, 2025
- UPLOAD Comment letter from SEC staff Jul 16, 2025
- ARS Annual report sent to shareholders May 12, 2025
Everything here comes from Monopar Therapeutics's own filings on SEC EDGAR. The filing list is rechecked every hour.